Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

10.46
+0.54505.50%
Volume:1.04M
Turnover:11.10M
Market Cap:607.84M
PE:-4.24
High:11.00
Open:10.77
Low:10.21
Close:9.91
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:3.96
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.47
PE(LYR):-4.63

Loading ...

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

GlobeNewswire
·
Jul 29

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Jul 29

Capricor Therapeutics Shares Fall After B. Riley, Roth Capital Downgrades

MT Newswires Live
·
Jul 29

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63

MT Newswires Live
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (CAPR) and Thermo Fisher (TMO)

TIPRANKS
·
Jul 28

Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital

TIPRANKS
·
Jul 28

Capricor Therapeutics Down over 63%, on Pace for Largest Percent Decrease Since February 2007

Dow Jones
·
Jul 28

Capricor Publishes Advisory Committee Presentation on Deramiocel Clinical Data in Duchenne Muscular Dystrophy

Reuters
·
Jul 27

Capricor Disputes FDA Post-hoc Analyses of Deramiocel Data Ahead of July 29 Advisory Panel

Reuters
·
Jul 27

Capricor Therapeutics Shares Slide on Negative FDA Comments

Dow Jones
·
Jul 27

Capricor Therapeutics plunges after FDA posts deramiocel briefing notes

TIPRANKS
·
Jul 27

Oppenheimer would own Capricor Therapeutics into committee meeting

TIPRANKS
·
Jul 27

B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Jul 27

Capricor Therapeutics Shares Fall 68% After US FDA Flags Concerns over Its Duchenne Therapy

THOMSON REUTERS
·
Jul 27

FDA Staff Flags Concerns for Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 27

Capricor Therapeutics Shares Fall 60% Premarket After FDA Staff Review Says Data for Co's Duchenne Cell Therapy Does not Provide Substantial Evidence of Effectiveness

THOMSON REUTERS
·
Jul 27

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Simply Wall St.
·
Jul 27

Longeveron Elects Deborah Ascheim to Board of Directors

Reuters
·
Jul 23

Capricor Therapeutics Signs Strategic Headquarters Lease Agreement

TIPRANKS
·
Jul 15

Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus

Simply Wall St.
·
Jul 05